Novo files N8-GP in the US and EU
Novo Nordisk has filed regulatory applications in the US and European Union seeking approval to market N8-GP for the treatment of haemophilia
Read More
Tag: Factor VIII
EU nod for Shire’s longer-acting haemophilia A therapy
Shire’s Adynovi has been approved for use in Europe for on-demand and prophylactic use in patients 12 years and older with the rare bleeding disorder haemophilia A.
Read More
Shire, Rani to develop oral factor VIII therapy
Shire and Rani Therapeutics have signed a deal to work on developing an orally-delivered therapy for patients with hemophilia A.
Read More
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
